Targeting cytokine networks in KRAS-driven tumorigenesis

Expert Review of Anticancer Therapy

Volumn 14, Issue 8, 2014, Pages 869-871

  Golay, Hadrien G ^a,b   Barbie, David A ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b EPFL   (Switzerland)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

cytokines; JAK; KRAS; targeted therapy; TBK1 IKKepsilon

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; RANTES; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ANGIOGENESIS; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RELEASE; GENE FUNCTION; HUMAN; METASTASIS; ONCOGENE K RAS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; DRUG DESIGN; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOKINES; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84905001999     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.928596     Document Type: Review

References (20)

1. Huang H, Daniluk J, Liu Y, et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene 2014;33(4): 532-5
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014; 64(1):9-29
3. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014;26(1):54-74
4. Ancrile BB, O'Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: A new target of anti-cancer therapeutics. Mol Interv 2008;8(1):22-7
5. Tan X, Carretero J, Chen Z, et al. Loss of p53 attenuates the contribution of il-6 deletion on suppressed tumor progression and extended survival in kras-driven murine lung cancer. PLoS One 2013;8(11):e80885
6. Lesina M, Kurkowski Magdalena U, Ludes K, et al. Stat3/socs3 activation by il-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19(4):456-69
7. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in kras-induced pancreatic tumorigenesis. Cancer Res 2011;71(14):5020-9
8. Gong L, Cumpian AC, da Silva Caetano M, et al. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer 2013;12(1):154
9. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449(7162):557-63
10. Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014;4(4):452-65
11. Ling J, Kang YA, Zhao R, et al. Krasg12d-induced ikk2/b/nf-kb activation by il-1a and p62 feed forward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21(1):105-20
12. Daniluk J, Liu Y, Deng D, et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 2012;122(4):1519-28
13. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462(7269):104-7
14. Xue W, Meylan E, Oliver TG, et al. Response and Resistance to NF-B. Inhibitors in Mouse Models of Lung Adenocarcinoma. Cancer Discov 2011;1(3): 236-47
15. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462(7269):108-12
16. Chien Y, Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the ikb family kinase tbk1 couples innate immune signaling to tumor cell survival. Cell 2006; 127(1):157-70
17. Guo J, Kim D, Gao J, et al. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene 2012; 32(2):151-9
18. Strickson S, Campbell David G, Emmerich Christoph H, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem J 2013;451(3):427-37
19. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 2012;366(9):844-6
20. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27(6):1322-7